Mabwell’s 9MW2821 gains FDA fast track status for breast cancer
The US Food and Drug Administration (FDA) has granted fast track designation to Mabwell’s antibody-drug conjugate (ADC).
The US Food and Drug Administration (FDA) has granted fast track designation to Mabwell’s antibody-drug conjugate (ADC).
What's Your Reaction?
